| Category: Equity: Sectoral-Pharma and Healthcare |
| Launch Date: 05-10-2023 |
| Asset Class: Equity |
| Benchmark: BSE Healthcare TRI |
| Expense Ratio: 2.17% As on (31-10-2024) |
| Status: Open Ended Schemes |
| Minimum Investment: 100.0 |
| Minimum Topup: 100.0 |
| Total Assets: 1,303 Cr As on (30-09-2024) |
| Turn over: |
| 1-Year Ret (%) | 3-Yrs Ret (%) | 5-Yrs Ret (%) | 10-Yrs Ret (%) | Since Launch Ret (%) | |
|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Growth Option | 59.64 | - | - | - | 57.24 |
| Benchmark | - | - | - | - | - |
| Equity: Sectoral-Pharma and Healthcare | 51.35 | 20.39 | 28.4 | 14.02 | 26.88 |
Dhruv Muchhal, Nikhil Mathur
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Rolling returns are the annualized returns of the scheme taken for a specified period (rolling returns period) on every day/week/month and taken till the last day of the duration. In this chart we are showing the annualized returns over the rolling returns period on every day from the start date and comparing it with the benchmark. Rolling returns is the best measure of a fund's performance. Trailing returns have a recency bias and point to point returns are specific to the period in consideration. Rolling returns, on the other hand, measures the fund's absolute and relative performance across all timescales, without bias.
| Key Statistics | Volatility | Sharpe Ratio | Alpha | Beta | Yield to Maturity | Average Maturity |
|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Growth Option | - | - | - | - | - | - |
| Equity: Sectoral-Pharma and Healthcare | - | - | - | - | - | - |